Not a "drug safety-testing lab" — compliance validation infrastructure. GLP is the only node that connects both drug compliance (ICH) and device compliance (ISO 10993), making it the hub for the entire chain.
GLP safety evaluation is carried out at the Yangtze River Delta National Innovation Center for Drug Safety Evaluation Technology. On the device path the platform operates within that national innovation system rather than as an outside client of it, and handles study design, organoid pre-screening and submission coordination. On the drug path, preclinical studies are carried out at GLP-accredited CRO partner centres as part of the platform.
Organoid technology serves as a front-end pre-screening tool for GLP, filtering out ineffective candidate molecules before formal animal testing begins — significantly lowering failure rates and costs, while also supplying mechanistic data that supports GLP reports.
Through our deep partnership with SinoGenoMax (National Human Genome Center, North), multi-omics — transcriptomics, metagenomics, methylation and liquid-biopsy profiling — sharpens target and biomarker selection up front. Better-defined hypotheses enter the GLP phase, so fewer studies are wasted on the wrong question.
For drug-side programmes, a GLP-accredited CRO partner — NMPA 10 full accreditations, OECD GLP, AAALAC, CMA — works through the platform in a deep partnership, with joint-name laboratories carrying out preclinical studies.
On the device path, nonclinical safety evaluation stays inside the platform's own system. On the drug path — safety pharmacology, toxicology and pharmacokinetics for an IND package, antibody discovery, radiopharmaceutical development (CRDMO) — the work runs through the platform's deep partnership with GLP-accredited CRO resources. These hold NMPA 10 GLP accreditations, OECD GLP, AAALAC, CMA, A2LA ISO 15189 and CAP across a multi-site GLP network. Specialty platforms include radiopharmaceuticals, ophthalmology, inhalation, CNS/neurological, cell & gene therapy, PROTAC/ADC/mRNA. You contract with Seno.Bio: one plan, one contract, one accountable partner, instead of managing a separate set of vendors for the drug programme.
In this deep partnership, preclinical studies are carried out at joint-name laboratories — the drug path is delivered as part of the platform, and Seno.Bio is your contract partner.
GLP safety evaluation is carried out at an established national evaluation center inside our own system.
The in-system center that carries out the platform’s GLP safety evaluation work is led by Prof. Liao Mingyang. His positions and recognitions are held at national evaluation and regulatory bodies:
What this means for your project: the GLP report supporting your submission is issued by an established national evaluation center within our own system — you are not being handed off to a third-party lab. The platform handles study design, organoid pre-screening ahead of the GLP phase, and submission coordination.